Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 3 Comments »
A paper in the journal Oncotarget has suggested that patients who have progressed on treatment with enzalutamide (Xtandi) may be good candidates for treatment with one of the checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), or even ipilimumab (Yervoy). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, checkpoiny, CRPC, enzalutamide, inhibitor, resistant | Leave a comment »
ASCO has just released a new set of provisional guidance (a “provisional clinical opinion” or PCO) on the second-line treatment of men with chemotherapy-naive, castration-resistant prostate cancer (CRPC), i.e., men who are progressing on initial androgen deprivation therapy (ADT or “hormone” therapy) but who haven’t had docetaxel-based chemotherapy yet. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ASCO, castration-resistant, chemotherapy-naïve, CRPC, guidance | 4 Comments »
According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: CRPC, development, drug, Minnelide, triptolide | 5 Comments »
Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, castration-resistant, CRPC, dutasteride, metsatatic | 6 Comments »
Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, Fortis | Leave a comment »
A new article in the journal Supportive Care in Cancer makes the point that informational needs and resources for men dealing with metastatic, castration-resistant prostate cancer continue to be relatively poor — a fact that we would not disagree with. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: care, CRPC, mCRPC, needs, resources, support | 9 Comments »
A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, everolimus, outcome, trial | 1 Comment »
According to a media release issued yesterday, Arno Therapeutics has moved its investigational drug onapristone into the Phase II part of its initial Phase I/II clinical trial in the treatment of very late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: anti-progestin, Arno, castration-resistant, CRPC, onapristone, trial | Leave a comment »
The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. … READ MORE …
Filed under: Management, Treatment | Tagged: castration-resistant, CRPC, estramustine, mitoxantrone, Treatment | Leave a comment »
A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, chemotherapy, CRPC | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 